This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: September 15th, 2010 - September 15th, 2011
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.
At the completion of this activity participants should be able to:
- Explain the impact of key data from ASCO 2010 on payers and providers regarding chronic myelogenous leukemia (CML)
- Assess potential clinical, business, and regulatory changes in CML
- Discuss patient-centered, value-based care for CML
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-10-054-H01-P.
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.
The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.
Michael Mauro, MD, has received research grants from, and is a consultant to, Bristol-Myers Squibb and Novartis Oncology.
*Content will include non-FDA-approved uses.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.